Celecoxib: Difference between revisions
ClaireLewis (talk | contribs) |
Neil.m.young (talk | contribs) (Text replacement - "0 mg" to "0mg") |
||
| Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
*[[Osteoarthritis]]: | *[[Osteoarthritis]]: 200mg PO qd | ||
*[[Rheumatoid arthritis]]: 100- | *[[Rheumatoid arthritis]]: 100-200mg PO bid | ||
**Use lowest effective dose, shortest effective treatment duration | **Use lowest effective dose, shortest effective treatment duration | ||
**Consider starting at 50% of lowest dose if poor CYP2C9 metabolizer | **Consider starting at 50% of lowest dose if poor CYP2C9 metabolizer | ||
*[[Ankylosing spondylitis]]: | *[[Ankylosing spondylitis]]: 200mg PO qd | ||
**Max: | **Max: 400mg/day | ||
*[[Dysmenorrhea]]: | *[[Dysmenorrhea]]: 200mg PO bid | ||
**Start: | **Start: 400mg PO x1, may give additional 200mg on day 1 if needed | ||
*Pain, acute: | *Pain, acute: 200mg PO bid | ||
**Start: | **Start: 400mg PO x1, may give additional 200mg on day 1 if needed | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
===Only for ages > 2 years old=== | ===Only for ages > 2 years old=== | ||
*[[Juvenile idiopathic arthritis ]] | *[[Juvenile idiopathic arthritis ]] | ||
**10-25 kg]: | **10-25 kg]: 50mg PO bid | ||
**>25 kg: | **>25 kg: 100mg PO bid | ||
==Special Populations== | ==Special Populations== | ||
Revision as of 01:25, 19 July 2016
Administration
- Type: Nonsteroidal anti-inflammatory drugs (NSAID), COX-2 Selective
- Dosage Forms: 50,100,200,400
- Routes of Administration: Oral
- Common Trade Names: CeleBREX
Adult Dosing
- Osteoarthritis: 200mg PO qd
- Rheumatoid arthritis: 100-200mg PO bid
- Use lowest effective dose, shortest effective treatment duration
- Consider starting at 50% of lowest dose if poor CYP2C9 metabolizer
- Ankylosing spondylitis: 200mg PO qd
- Max: 400mg/day
- Dysmenorrhea: 200mg PO bid
- Start: 400mg PO x1, may give additional 200mg on day 1 if needed
- Pain, acute: 200mg PO bid
- Start: 400mg PO x1, may give additional 200mg on day 1 if needed
Pediatric Dosing
Only for ages > 2 years old
- Juvenile idiopathic arthritis
- 10-25 kg]: 50mg PO bid
- >25 kg: 100mg PO bid
Special Populations
- Pregnancy Risk Factor:
- C (prior to 30 weeks gestation)
- D (≥30 weeks gestation)
Renal Dosing
- Avoid use in severe renal impairment
Hepatic Dosing
- Adult:Child-Pugh Class B: decrease dose 50%; Child-Pugh Class C: avoid use
Contraindications
- hypersens. to drug/class/compon.
- hypersens. to sulfonamides
- ASA or NSAID-induced asthma or urticaria
- aspirin triad
- pregnancy starting at 30 wk gestation
- CABG surgery periop use
- GI bleeding
Adverse Reactions
Serious
- GI bleeding
- GI perforation/ulcer
- MI
- stroke
- thromboembolism
Common
Pharmacology
- Half-life: 11hr
- Metabolism: CYP450
- Excretion: feces, urine
Mechanism of Action
Comments
See Also
References
<Epocrates, UpToDate>
